<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82770">
  <stage>Registered</stage>
  <submitdate>16/04/2008</submitdate>
  <approvaldate>18/04/2008</approvaldate>
  <actrnumber>ACTRN12608000208303</actrnumber>
  <trial_identification>
    <studytitle>Evaluate the effectiveness and safety of Cpn10 in subjects with moderate to severe rheumatoid arthritis despite treatment with methotrexate</studytitle>
    <scientifictitle>A multi-centre, randomised, double blind, placebo-controlled, parallel group, phase IIa clinical trial to assess the efficacy and safety of Cpn10 administered as twice weekly subcutaneous injections in subjects with Rheumatoid Arthritis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Rheumatoid Arthritis (RA)</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Rheumatoid arthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Cpn10 25 mg subcutaneous injection twice per week for 24 weeks.
Cpn10 75 mg subcutaneous injection twice per week for 24 weeks.</interventions>
    <comparator>All subjects will be taking methotrexate, either oral or intramuscular, at the maximum tolerated dose which is tailored for each individual subject.  The control group will be receiving placebo Cpn10.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percentage of subjects achieving at least a 20% improvement in core disease measures according to the American College of Rheumatology (ACR) response criteria-ACR20.</outcome>
      <timepoint>at 12 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of subjects achieving an ACR20 response.</outcome>
      <timepoint>at 2, 4, 6, 8, 16, 20 and 24 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of subjects achieving at least a 50% improvement in core disease measures according to ACR- ACR50 response.</outcome>
      <timepoint>at 2, 4, 6, 8, 10, 12 ,16, 20 and 24 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of subjects achieving at least a 70% improvement in core disease measures according to ACR- ACR70 response.</outcome>
      <timepoint>at 2, 4, 6, 8, 10, 12, 16, 20 and 24 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Disease Activity Score (DAS) using the 28 joint count- DAS28 score and DAS responder status.</outcome>
      <timepoint>at 2, 4, 6, 8, 10, 12, 16, 20 and 24 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Tender and swollen joint counts</outcome>
      <timepoint>at 2, 4, 6, 8, 10, 12, 16, 20 and 24 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Erythrocyte sedimentation rate (ESR)</outcome>
      <timepoint>at 2, 4, 6, 8, 10, 12, 16, 20 and 24 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>C-reactive protein (CRP) level measured in the blood</outcome>
      <timepoint>at 2, 4, 6, 8, 10, 12, 16, 20 and 24 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Health assessment questionnaire (HAQ)</outcome>
      <timepoint>at 2, 4, 6, 8, 10, 12, 16, 20 and 24 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Length of Early morning joint stiffness recorded by the subject in a diary for the last week.</outcome>
      <timepoint>at 2, 4, 6, 8, 10, 12, 16, 20 and 24 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Physician Global Assessment</outcome>
      <timepoint>at 2, 4, 6, 8, 10, 12, 16, 20 and 24 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patient Global assessment of disease activity, pain and fatigue.</outcome>
      <timepoint>at 2, 4, 6, 8, 10, 12, 16, 20 and 24 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Short form 36 questionnaire (SF-36)</outcome>
      <timepoint>at 4, 8, 12, 16, 20 and 24 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>FACIT- fatigue scale</outcome>
      <timepoint>at 4, 8, 12, 16, 20 and 24 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>American College of Rheumatology - N (ACR-N)
ACR-N is a continuous index that can detect smaller variations in improvement and deterioration and therefore may be a more sensitive measure of efficacy than the standard ACR responses.</outcome>
      <timepoint>at 2, 4, 8, 12, 16, 20 and 24 Weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Diagnosis of RA according to the American College of Rheumatology with 
RA Functional Class I-III.
2. Diagnosed at least 6 months prior to screening.
3. Failed at least one disease modifying anti-rheumatic drug (DMARD), but not more than five.
4. Taking methotrexate for at least 3 months prior to screening and at a stable maximum tolerated dose for at least 1 month prior to screening.
5. Any other DMARD (if taken) must have been taken for at least 3 months and be taken at a stable dose for at least one month prior to screening.
6. Active RA despite stable methotrexate at a maximum tolerated dose. Active RA defined as a DAS28&gt;3.2 and at least 6 tender and swollen joints of 68 examined and either an ESR&gt;25mm/hr or a CRP&gt;10mg/mL.
7. weight &lt;120kg.
8. Prednisolone (or equivalent) (if taken) must be at a dose of no more than 10 mg/ day and stable for at least one month prior to screening.
9. Non-steroidal anti-inflammatory drugs (NSAIDS) (if taken) must be at a stable dose for at least one month prior to screening.
10. In general good health other than RA.
11. Use a medically reliable method of contraception throughout the study.
12. Provide written informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Diagnosed with juvenile RA. 2. History of allergic or anaphylatic reactions to Cpn10. 3. Treatment with any DMARD other than stable doses of hydroxchloroquine, sulphasalazine, leflunomide, azothioprine, minocycline, gold or methotrexate within 3 months of screening. 4. prior treatment with more than one biological agent for RA. 5. Treatment with a small molecule investigational product within 28 days prior to screening or 5 times the half-life of the drug (whichever is longer) prior to day 0. 6. administration of intra-articular or parenteral glucocorticoids within 4 weeks of screening. 7. Dose of NSAID higher than the maximum recommended dose in the product information. 8. Current use of narcotic analgesics other than codeine or dextropropoxyphene at screening. 9. Active or latent bacterial, fungal, viral or atypical mycobacterial infections. 10. History of opportunistic infections (systemic fungal infections, parasites) within the past 6 months. 11. History of malignancy within the past 5 years (other than basal or squamous cell carcinoma or adequately treated carcinoma of the cervix). 12. Any live (attenuated) or killed virus or bacterial vaccines within 14 days of day 0. 13. Clinical evidence of hepatic insufficiency, liver cirrhosis or fibrosis. 14. History of viral hepatitis within 1 year prior to screening or history of drug-induced liver injury at any time prior to screening. 15. History of substance abuse within the last 5 years. 16. Female who is lactating or pregnant. 17. Seropositive test to HIV, Hepatitis B or Hepatitis C at screening. 18. White cell count &lt; 3.2 x10^9/L. 19. Platelet count &lt; 125 x 10^9/L. 20. Haemoglobin &lt; 85 g/L. 21. Aspartate transaminase (AST), Alanine transaminase (ALT), Alkalline phosphatase (ALP) or serum creatinine &gt; 2 times the upper limit of the normal range. 22. History of active tuberculosis confirmed by a chest x-ray and Quantiferon TB Gold test at screening. 23. Treatment with a biological agent for RA within 3 months of day 0. 24. Vaccines or allergy desensitisation therapy within 14 days of day 0. 25. Significant concurrent medical conditions which the investigator believes places the subject at an unaccceptable risk for participation in the trial.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation by phone</concealment>
    <sequence>Stratified according to disease duration (&lt;2 or &gt; 2 years) and centre.
Randomisation by a minimisation method.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Rescue arm at 12 weeks for non-responders. There are two sub-studies (pharmacokinetic and a pharmacodynamic) at selected centres who have agreed to participate. 30 subjects of the 150 in the trial will be recruited to the pharmacokinetic sub-study and 50 subjects will be recruited to the pharmacodynamic sub-study</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/05/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>150</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>4558</postcode>
    <postcode>3144</postcode>
    <postcode>4870</postcode>
    <postcode>4102</postcode>
    <postcode>5011</postcode>
    <postcode>6008</postcode>
    <postcode>2194</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland, Middlemore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Rotarua</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Hamilton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>North Shore Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Nelson</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>CBio Limited</primarysponsorname>
    <primarysponsoraddress>85 Brandl St
Eight Mile Plains QLD 4113</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>CBio Limited</fundingname>
      <fundingaddress>85 Brandl St
Eight Mile Plains QLD 4113</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Redcliffe-Caboolture Ethics Committee</ethicname>
      <ethicaddress>Redcliffe Hospital
Anzac Ave
Redcliffe QLD 4020</ethicaddress>
      <ethicapprovaldate>6/02/2008</ethicapprovaldate>
      <hrec>EC00171</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Bellberry Human Research Ethics Committee</ethicname>
      <ethicaddress>71 Anzac Highway
Ashford SA 5035</ethicaddress>
      <ethicapprovaldate>29/11/2007</ethicapprovaldate>
      <hrec>EC00372</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Cairns Base Hospital Ethics Committee</ethicname>
      <ethicaddress>Cairns Base Hospital
The Esplanade
Cairns QLD 4870</ethicaddress>
      <ethicapprovaldate>13/12/2007</ethicapprovaldate>
      <hrec>EC00157</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Princess Alexandra Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>Princess Alexandra Hospital
Ipswich Rd
Woolloongabba QLD 4102</ethicaddress>
      <ethicapprovaldate>5/11/2007</ethicapprovaldate>
      <hrec>EC00167</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Ethics of Human Research Committee (TQEH &amp; LMH)</ethicname>
      <ethicaddress>The Queen Elizabeth Hospital
28 Woodville Rd
Woodvile South SA 5011</ethicaddress>
      <ethicapprovaldate>14/03/2008</ethicapprovaldate>
      <hrec>EC00190</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Perth Hospital Ethics Committee</ethicname>
      <ethicaddress>Kirkman House
Wellington St Campus
Box X2213 GPO, Perth 6847</ethicaddress>
      <ethicapprovaldate>15/02/2008</ethicapprovaldate>
      <hrec>EC00270</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Multi-Region Ethics Committee</ethicname>
      <ethicaddress>Ministry of Health
Level 2, 1-3 The Terrace
PO Box 5013 Wellington</ethicaddress>
      <ethicapprovaldate>15/02/2008</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Gold Coast Hospital Health Service District Human Research Ethics Committee</ethicname>
      <ethicaddress>108 Nerang Street
Southport QLD 4215</ethicaddress>
      <ethicapprovaldate>2/07/2009</ethicapprovaldate>
      <hrec>New ethics HREC. Please modify.</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Brisbane and Women?s Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>Level 7, Block 7, Royal Brisbane and Women?s Hospital, Butterfield Street
Herston  4029</ethicaddress>
      <ethicapprovaldate>3/08/2009</ethicapprovaldate>
      <hrec>New ethics HREC. Please modify.</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Institute for Rheumatology</ethicname>
      <ethicaddress>Belgrade, Resavska 69</ethicaddress>
      <ethicapprovaldate>12/12/2009</ethicapprovaldate>
      <hrec>New ethics HREC. Please modify.</hrec>
      <ethicsubmitdate />
      <ethiccountry>Serbia and Montenegro</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Institute for Treatment and Rehabilitation</ethicname>
      <ethicaddress>Srpskih junaka 2
18205 Niska Banja</ethicaddress>
      <ethicapprovaldate>29/12/2009</ethicapprovaldate>
      <hrec>New ethics HREC. Please modify.</hrec>
      <ethicsubmitdate />
      <ethiccountry>Serbia and Montenegro</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Clinical-Hospital Centre Zemun- Belgrade</ethicname>
      <ethicaddress>Vukova9, 11080
Zemun Belgrade</ethicaddress>
      <ethicapprovaldate>3/12/2009</ethicapprovaldate>
      <hrec>New ethics HREC. Please modify.</hrec>
      <ethicsubmitdate />
      <ethiccountry>Serbia and Montenegro</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>University Clinical Centre Banja Luka</ethicname>
      <ethicaddress>12 beba bb,Banja Luka 78000</ethicaddress>
      <ethicapprovaldate>28/01/2010</ethicapprovaldate>
      <hrec>New ethics HREC. Please modify.</hrec>
      <ethicsubmitdate />
      <ethiccountry>Bosnia and Herzegovina</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>University Clinical Centre Tuzla,</ethicname>
      <ethicaddress>Trnovac bb,Tuzla 75000</ethicaddress>
      <ethicapprovaldate>28/01/2010</ethicapprovaldate>
      <hrec>New ethics HREC. Please modify.</hrec>
      <ethicsubmitdate />
      <ethiccountry>Bosnia and Herzegovina</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>University Clinical Centre Sarajevo</ethicname>
      <ethicaddress>Bolnicka 25,Sarajevo 71000</ethicaddress>
      <ethicapprovaldate>28/01/2010</ethicapprovaldate>
      <hrec>New ethics HREC. Please modify.</hrec>
      <ethicsubmitdate />
      <ethiccountry>Bosnia and Herzegovina</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>University Clinical Hospital Foca</ethicname>
      <ethicaddress>Studentska bb,Foca 73300</ethicaddress>
      <ethicapprovaldate>28/01/2010</ethicapprovaldate>
      <hrec>New ethics HREC. Please modify.</hrec>
      <ethicsubmitdate />
      <ethiccountry>Bosnia and Herzegovina</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Medulla Chemotherapy and Immunotherapy Clinic</ethicname>
      <ethicaddress>6, Jikia str.Tbilisi, 0186</ethicaddress>
      <ethicapprovaldate>3/02/2010</ethicapprovaldate>
      <hrec>New ethics HREC. Please modify.</hrec>
      <ethicsubmitdate />
      <ethiccountry>Georgia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Ltd Academician V Tsitlanadze Scientifi</ethicname>
      <ethicaddress>51, Uznadze str. Tbilisi, 0102</ethicaddress>
      <ethicapprovaldate>3/02/2010</ethicapprovaldate>
      <hrec>New ethics HREC. Please modify.</hrec>
      <ethicsubmitdate />
      <ethiccountry>Georgia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bronwyn Williams</name>
      <address>CBio Limited
85 Brandl St
Eight Mile Plains QLD 4113</address>
      <phone>+61 7 3841 4844</phone>
      <fax>+61 7 3841 8189</fax>
      <email>bronwyn.williams@cbio.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Melanie Farris</name>
      <address>CBio Limited
85 Brandl St
Eight Mile Plains QLD 4113</address>
      <phone>+61 7 3481 4844</phone>
      <fax>+61 7 3841 8189</fax>
      <email>melanie.farris@cbio.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Bronwyn Williams</name>
      <address>CBio Limited
85 Brandl St 
Eight Mile Plains QLD 4113</address>
      <phone>+61 7 3841 4844</phone>
      <fax>+61 7 3841 8189</fax>
      <email>bronwyn.williams@cbio.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>